Sign Up to like & get
recommendations!
2
Published in 2022 at "Blood"
DOI: 10.1182/blood.2021013563
Abstract: Severe hemophilia A is routinely managed with prophylactic replacement of factor VIII (F8), but a significant minority of patients develop anti-F8 antibodies. Extended half-life (EHL) products were developed to reduce the frequency of infusions required.…
read more here.
Keywords:
first study;
life rfviiifc;
half life;
study extended ... See more keywords